サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1588313

脊椎バイオロジクスの市場規模、シェア、動向分析レポート：製品別、手術別、最終用途別、地域別、セグメント予測、2025年～2030年

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix), By Surgery, By End Use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
脊椎バイオロジクスの市場規模、シェア、動向分析レポート：製品別、手術別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2024年10月30日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脊椎バイオロジクス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、脊椎バイオロジクスの世界市場規模は2030年までに43億8,000万米ドルに達し、2025年から2030年までのCAGRは4.9%で拡大すると推定されています。

この市場を牽引しているのは、主に脊椎損傷の発生率の増加です。脊椎変形の有病率は先進国でも低開発国でも上昇傾向にあり、その結果、手術件数が増加しています。これは脊椎バイオロジクス市場に好影響を与えています。

これとは別に、脊椎固定手術における生物学的製剤の多くの利点、例えば術後時間の最小化や細胞増殖を活性化する能力などについての認識が高まっていることも、市場を後押ししています。生体材料や骨移植代替物は、脊柱変形に対する治療の選択肢として採用されつつあります。脊椎疾患を患う高齢者人口の割合が増加し、治療法としてこれらの製品の採用が増加していることから、予測期間中に脊椎バイオロジクスの市場が拡大すると予想されます。

老年人口は脊椎すべり症や椎間板変性症になりやすいです。これに加え、交通事故やスポーツ外傷による外傷症例の増加が、脊椎バイオロジクスの需要を押し上げています。2018年に出版された低侵襲手術（MIS）のオープンアクセスジャーナルによると、低侵襲技術は幅広い脊椎病理の治療に採用されています。米国では年間約40万例が実施されており、脊椎固定術は脊椎外傷、変性疾患、腫瘍、構造異常に対して最も一般的に実施され、確立された治療法の1つであることが判明しています。

脊椎バイオロジクス市場のハイライト

  • 脊椎移植片分野が市場を独占し、2024年の世界売上高の58.7%を占めました。この優位性は、同種移植片の使用に伴う多くの利点に起因しています。
  • 病院セグメントが2024年の市場を独占しました。このセグメントの主な要因は、これらの施設で行われる脊椎固定術の件数が増加していることです。
  • 北米が市場を独占し、2024年のシェアは48.2%でした。同市場の成長は、安定した経済成長、低侵襲手術の採用増加、椎間板関連問題、脊柱管狭窄症、脊椎すべり症などの脊椎疾患の有病率の上昇に起因しています。
  • アジア太平洋地域は、患者数が多く、生物学的製剤の利点について患者や外科医の間で認識が高まっていることから、市場の急成長が予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 脊椎バイオロジクス市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 脊椎バイオロジクス市場：製品ビジネス分析

  • 製品市場シェア、2024年および2030年
  • 製品セグメントダッシュボード
  • 市場規模と予測および動向分析、製品別、2018～2030年
  • 脊椎同種移植
  • 骨移植代替品
  • 細胞ベースのマトリックス

第5章 脊椎バイオロジクス市場：手術ビジネス分析

  • 手術の市場シェア、2024年と2030年
  • 手術セグメントダッシュボード
  • 市場規模と予測および動向分析、手術別、2018～2030年
  • 頸椎前方椎間板切除術および固定術（ACDF）
  • 経椎間孔腰椎椎体間固定術（TLIF）
  • 腰椎後方椎体間固定術（PLIF）
  • 腰椎前方固定術（ALIF）
  • 側方腰椎椎体間固定術（LLIF）

第6章 脊椎バイオロジクス市場：最終用途ビジネス分析

  • 最終用途市場シェア、2024年および2030年
  • 最終用途セグメントダッシュボード
  • 市場規模と予測および動向分析、最終用途別、2018～2030年
  • 病院
  • 外来施設

第7章 脊椎バイオロジクス市場：製品別の地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 国別、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 脊椎バイオロジクス市場：手術別の地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 国別、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 脊椎バイオロジクス市場：最終用途別の地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 国別、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 参入企業概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Stryker
    • NuVasive, Inc.
    • Orthofix
    • DePuy Synthes（Johnson &Johnson）
    • Exactech, Inc.
    • Zimmer Biomet
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global spine biologics market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 5. Global spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 6. Global spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 7. North America spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 8. North America spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 9. North America spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 10. North America spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 11. U.S. spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 12. U.S. spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 13. U.S. spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 14. Canada spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 15. Canada spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 16. Canada spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 17. Mexico spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 18. Mexico spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 19. Mexico spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 20. Europe spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Europe spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 22. Europe spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 23. Europe spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 24. UK spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 25. UK spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 26. UK spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 27. Germany spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 28. Germany spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 29. Germany spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 30. France spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 31. France spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 32. France spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 33. Italy spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 34. Italy spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 35. Italy spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 36. Spain spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 37. Spain spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 38. Spain spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 39. Norway spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 40. Norway spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 41. Norway spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 42. Denmark spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 43. Denmark spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 44. Denmark spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 45. Sweden spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 46. Sweden spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 47. Sweden spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 48. Asia Pacific spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 49. Asia Pacific spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 50. Asia Pacific spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 51. Asia Pacific spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 52. Japan spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 53. Japan spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 54. Japan spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 55. China spine biologics market, by product, 2018-2030 (USD Billion)
  • Table 56. China spine biologics market, by surgery, 2018-2030 (USD Billion)
  • Table 57. China spine biologics market, by end-use, 2018-2030 (USD Billion)
  • Table 58. India spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 59. India spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 60. India spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 61. Australia spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 62. Australia spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 63. Australia spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 64. South Korea spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 65. South Korea spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 66. South Korea spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 67. Thailand spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 68. Thailand spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 69. Thailand spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 70. Latin America spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 71. Latin America spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 72. Latin America spine biologics market, by surgery, 2018 - 2030 (USD Billion
  • Table 73. Latin America spine biologics market, by end-use, 2018 - 2030 (USD Billion
  • Table 74. Brazil spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 75. Brazil spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 76. Brazil spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 77. Argentina spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 78. Argentina spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 79. Argentina spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 80. Middle East & Africa spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 81. Middle East & Africa spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 82. Middle East & Africa spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 83. Middle East & Africa spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 84. South Africa spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 85. South Africa spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 86. South Africa spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 87. Saudi Arabia spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 88. Saudi Arabia spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 89. Saudi Arabia spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 90. UAE spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 91. UAE spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 92. UAE spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 93. Kuwait spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 94. Kuwait spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 95. Kuwait spine biologics market, by end-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Spine biologics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product outlook (USD Billion)
  • Fig. 10 Transportation mode outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 Spine biologics market dynamics
  • Fig. 13 Spine biologics market: Porter's five forces analysis
  • Fig. 14 Spine biologics market: PESTLE analysis
  • Fig. 15 Spine biologics market: Product segment dashboard
  • Fig. 16 Spine biologics market: Product market share analysis, 2024 & 2030
  • Fig. 17 Spinal allografts market, 2018 - 2030 (USD Billion)
  • Fig. 18 Bone graft substitutes market, 2018 - 2030 (USD Billion)
  • Fig. 19 Cell-based matrix market, 2018 - 2030 (USD Billion)
  • Fig. 20 Spine biologics market: Surgery segment dashboard
  • Fig. 21 Spine biologics market: Surgery market share analysis, 2024 & 2030
  • Fig. 22 Anterior cervical discectomy and fusion (ACDF) market, 2018 - 2030 (USD Billion)
  • Fig. 23 Transforaminal lumbar interbody fusion (TLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 24 Posterior lumbar interbody fusion (PLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 25 Anterior lumbar interbody fusion (ALIF) market, 2018 - 2030 (USD Billion)
  • Fig. 26 Lateral lumbar interbody fusion (LLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 27 Spine biologics market: End use segment dashboard
  • Fig. 28 Spine biologics market: End use market share analysis, 2024 & 2030
  • Fig. 29 Hospitals market, 2018 - 2030 (USD Billion)
  • Fig. 30 Outpatient facilities market, 2018 - 2030 (USD Billion)
  • Fig. 31 Spine biologics market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 40 Europe spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 57 Asia Pacific spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 70 Latin America spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 75 MEA spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework
目次
Product Code: GVR-3-68038-588-5

Spine Biologics Market Growth & Trends:

The global spine biologics market size is estimated to reach USD 4.38 billion by 2030, expanding at a CAGR of 4.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

Spine Biologics Market Report Highlights:

  • The spinal allografts segment dominated the market and accounted for 58.7% of the global revenue in 2024. This dominance can be attributed to the numerous benefits associated with the usage of allografts.
  • The hospital segment dominated the market in 2024. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.
  • North America dominated the market and accounted for a 48.2% share in 2024. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.
  • Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Surgery
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Spine Biologics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Spine Biologics Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 4.4. Spinal Allografts
    • 4.4.1. Spinal Allografts Market, 2018 - 2030 (USD Billion)
      • 4.4.1.1. Machined Bones Allograft Market, 2018 - 2030 (USD Billion)
      • 4.4.1.2. Demineralized Bone Matrix Market, 2018 - 2030 (USD Billion)
  • 4.5. Bone Graft Substitutes
    • 4.5.1. Bone Graft Substitutes Market, 2018 - 2030 (USD Billion)
      • 4.5.1.1. Bone Morphogenetic Proteins Market, 2018 - 2030 (USD Billion)
      • 4.5.1.2. Synthetic Bone Grafts Market, 2018 - 2030 (USD Billion)
  • 4.6. Cell-based Matrix
    • 4.6.1. Cell-based Matrix Market, 2018 - 2030 (USD Billion)

Chapter 5. Spine Biologics Market: Surgery Business Analysis

  • 5.1. Surgery Market Share, 2024 & 2030
  • 5.2. Surgery Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Surgery, 2018 to 2030 (USD Billion)
  • 5.4. Anterior Cervical Discectomy and Fusion (ACDF)
    • 5.4.1. Anterior Cervical Discectomy and Fusion (ACDF) Market, 2018 - 2030 (USD Billion)
  • 5.5. Transforaminal Lumbar Interbody Fusion (TLIF)
    • 5.5.1. Transforaminal Lumbar Interbody Fusion (TLIF) Market, 2018 - 2030 (USD Billion)
  • 5.6. Posterior Lumbar Interbody Fusion (PLIF)
    • 5.6.1. Posterior Lumbar Interbody Fusion (PLIF) Market, 2018 - 2030 (USD Billion)
  • 5.7. Anterior Lumbar Interbody Fusion (ALIF)
    • 5.7.1. Anterior Lumbar Interbody Fusion (ALIF) Market, 2018 - 2030 (USD Billion)
  • 5.8. Lateral Lumbar Interbody Fusion (LLIF)
    • 5.8.1. Lateral Lumbar Interbody Fusion (LLIF) Market, 2018 - 2030 (USD Billion)

Chapter 6. Spine Biologics Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 6.5. Outpatient Facilities
    • 6.5.1. Outpatient Facilities Market, 2018 - 2030 (USD Billion)

Chapter 7. Spine Biologics Market: Regional Estimates & Trend Analysis by Product

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Spine Biologics Market: Regional Estimates & Trend Analysis by Surgery

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8. MEA
    • 8.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Spine Biologics Market: Regional Estimates & Trend Analysis by End Use

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.4. North America
    • 9.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Regulatory Framework
      • 9.4.2.3. Competitive Insights
      • 9.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Regulatory Framework
      • 9.4.3.3. Competitive Insights
      • 9.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Regulatory Framework
      • 9.4.4.3. Competitive Insights
      • 9.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5. Europe
    • 9.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Regulatory Framework
      • 9.5.2.3. Competitive Insights
      • 9.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Regulatory Framework
      • 9.5.3.3. Competitive Insights
      • 9.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Regulatory Framework
      • 9.5.4.3. Competitive Insights
      • 9.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Regulatory Framework
      • 9.5.5.3. Competitive Insights
      • 9.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Regulatory Framework
      • 9.5.6.3. Competitive Insights
      • 9.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.7. Norway
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Regulatory Framework
      • 9.5.7.3. Competitive Insights
      • 9.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.8. Denmark
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Regulatory Framework
      • 9.5.8.3. Competitive Insights
      • 9.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.9. Sweden
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Regulatory Framework
      • 9.5.9.3. Competitive Insights
      • 9.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Regulatory Framework
      • 9.6.2.3. Competitive Insights
      • 9.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Regulatory Framework
      • 9.6.3.3. Competitive Insights
      • 9.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Regulatory Framework
      • 9.6.4.3. Competitive Insights
      • 9.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.5. South Korea
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Regulatory Framework
      • 9.6.5.3. Competitive Insights
      • 9.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.6. Australia
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Regulatory Framework
      • 9.6.6.3. Competitive Insights
      • 9.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Regulatory Framework
      • 9.6.7.3. Competitive Insights
      • 9.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7. Latin America
    • 9.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Regulatory Framework
      • 9.7.2.3. Competitive Insights
      • 9.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Regulatory Framework
      • 9.7.3.3. Competitive Insights
      • 9.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8. MEA
    • 9.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Regulatory Framework
      • 9.8.2.3. Competitive Insights
      • 9.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Regulatory Framework
      • 9.8.3.3. Competitive Insights
      • 9.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Regulatory Framework
      • 9.8.4.3. Competitive Insights
      • 9.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Regulatory Framework
      • 9.8.5.3. Competitive Insights
      • 9.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Stryker
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. NuVasive, Inc.
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Orthofix
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. DePuy Synthes (Johnson & Johnson)
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Exactech, Inc.
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Zimmer Biomet
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives